EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

R V Moerman, S Arends, P M Meiners, E Brouwer, F K L Spijkervet, F G M Kroese, A Vissink, H Bootsma

Research output: Contribution to journalLetterAcademicpeer-review

38 Citations (Scopus)
15 Downloads (Pure)
Original languageEnglish
Pages (from-to)472-474
Number of pages3
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - Feb-2014


  • Antibodies, Monoclonal, Murine-Derived
  • Double-Blind Method
  • Humans
  • Immunologic Factors
  • Severity of Illness Index
  • Sjogren's Syndrome
  • Treatment Outcome

Cite this